Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications.
BACKGROUND
To determine the usefulness of the IgG z-score (age and sex-standardized serum IgG level) before intravenous gamma globulin therapy (IVGG) in predicting the occurrence or severity of coronary complications in Kawasaki disease (KD).


METHODS
A case-control study of clinical and laboratory findings with 88 children in the early stage of acute KD who received IVGG (100 or 200 mg/kg for 2-5 days) therapy. Of these, 20 cases had persistent coronary arterial lesions (small aneurysm, moderate aneurysm or large aneurysm persisting more than 1 month). The controls comprised 68 children with no coronary aneurysms or transient small aneurysm only observed within 1 month after the onset of KD. The association between serum levels of immunoglobulin G (IgG). IgM, IgA as well as other coronary risk factors previously reported and the occurrence of the coronary arterial lesions was evaluated using logistic regression analysis.


RESULTS
After adjustment for age, gender, total IVGG dose before the 9th illness day and other traditional coronary risk factors, the odds ratio for the persistent coronary aneurysm associated with lower serum IgG z-score (< -0.7485 vs > or = -0.7485), was 30.3 (95% confidence interval, 3.8-243.2). Furthermore, the serum IgG z-score was inversely correlated with the severity of the coronary arterial lesion.


CONCLUSIONS
The IgG z-score before IVGG therapy in the early stage of KD provides useful information on the risk factors for persistent coronary aneurysm and is a novel, additional indicator for therapy to prevent the coronary complications in acute KD.
Sawaji
Y
Y
Department of Pediatrics, Shimane Medical University, Izumo, Japan.
Haneda
N
N
Yamaguchi
S
S
Kajino
Y
Y
Kishida
K
K
Seto
S
S
Konishi
N
N
Waki
K
K
Baba
K
K
Arisawa
K
K
Kamiya
T
T
Mori
C
C
D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003323:Coronary Aneurysm / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D007262:Infusions, Intravenous; D007564:Japan; D016015:Logistic Models; D008297:Male; D009080:Mucocutaneous Lymph Node Syndrome / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D016017:Odds Ratio; D012720:Severity of Illness Index; D005719:gamma-Globulins / Q000627:therapeutic use*
D007074:Immunoglobulin G; D005719:gamma-Globulins